Mark Amster, MD
Dermatology · Brighton, MANPI 1518947068
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Galderma Laboratories, L.p. at 45.9% of the total. Among dermatology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 483 payments — averaging $56.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$13K
- AbbVie$4K
- Novartis$2K
- LEO Pharma Inc.$1K
- UCB, Inc.$1K
- Johnson & Johnson$1K
- plus $6K from 22 others
Across 1,266 payments — averaging $4061.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Incyte Corporation$1.6M
- Mitsubishi Tanabe Pharma Development America, Inc.$511K
- Bausch Health US, LLC$447K
- Janssen Research & Development, LLC$367K
- Amgen$324K
- Tanabe Pharma America, Inc.$294K
- plus $1.6M from 18 others
What the payments were for
- Consulting fees$1,8007%
- Speaking & faculty fees$10,46038%
- Travel & lodging$3,53613%
- Food & beverage$11,36842%
- Education$1901%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 23 | $12,550 |
| AbbVie | 88 | $3,736 |
| Novartis | 22 | $1,791 |
| LEO Pharma Inc. | 73 | $1,242 |
| UCB, Inc. | 50 | $1,199 |
| Johnson & Johnson | 39 | $1,052 |
| UCB GmbH | 8 | $996 |
| Incyte Corporation | 25 | $738 |
| Merck | 6 | $723 |
| E.r. Squibb & Sons, L.L.C. | 39 | $624 |
| Lilly USA, LLC | 21 | $472 |
| Pfizer | 22 | $414 |
| Amgen | 11 | $334 |
| Sanofi | 12 | $331 |
| Regeneron Healthcare Solutions, Inc. | 10 | $234 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 4 | $170 |
| Organon | 8 | $154 |
| Bristol Myers Squibb | 5 | $114 |
| Sun Pharmaceutical Industries Inc. | 4 | $111 |
| Boehringer Ingelheim | 2 | $61 |
| Dermavant Sciences, Inc. | 2 | $54 |
| Janssen Research & Development, LLC | 1 | $52 |
| VYNE Pharmaceuticals Inc. | 2 | $47 |
| Bausch Health US, LLC | 1 | $45 |
| Arcutis Biotherapeutics, Inc. | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Biofrontera Inc. | 1 | $19 |
| Strata Skin Sciences, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,355 in reported general payments places this provider in the 90th percentile of 552 dermatology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $262,006 |
| Dupixent PenDupilumab | 62 | $229,062 |
| Taltz AutoinjectorIxekizumab | 12 | $85,724 |
| Clobetasol Propionate | 86 | $5,679 |
| Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc | 122 | $4,745 |
| Tacrolimus | 27 | $4,149 |
| Betamethasone Dipropionate | 93 | $3,975 |
| Metronidazole | 53 | $3,217 |
| Fluorouracil | 40 | $2,084 |
| Ketoconazole | 64 | $1,237 |
| Tretinoin | 13 | $1,214 |
| Ciclopirox | 38 | $1,085 |
| Ammonium Lactate | 34 | $672 |
| Clindamycin Phosphate | 16 | $546 |
| Doxycycline Hyclate | 27 | $394 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Brighton
- John HarrisWorcester$15M
- Ethan LernerCharlestown$1.7M
- Michael KaminerChestnut Hill$1.1M
- Jeffrey SobellChestnut Hill$986K
- Erik DominguesFall River$736K
- Alexandra KimballBoston$680K
- Arash MostaghimiBoston$591K
- David GreensteinBeverly$540K
- Brian HiblerBoston$498K
- Maryanne SennaBoston$430K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.